Drug reference
obinutuzumab
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Drug class
Oncology (Monoclonal antibody(Oncology))
Mechanism of action
CD20-directed cytolytic antibody; upon binding to CD20, obinutuzumab mediates B-cell lysis through 1) engagement of immune effector cells, 2) by directly activating intracellular death signaling pathways and/or, 3) activation of the complement cascade
Common side effects
- Neutropenia
- Hyperkalemia
- Infusion related reactions
- Hypocalcemia
- Hyponatremia
- Creatinine increased
- AST/SGOT increased
Related conditions
Frequently asked questions
What drug class is obinutuzumab?
obinutuzumab belongs to: Oncology.
How does obinutuzumab work?
CD20-directed cytolytic antibody; upon binding to CD20, obinutuzumab mediates B-cell lysis through 1) engagement of immune effector cells, 2) by directly activating intracellular death signaling pathways and/or, 3) activation of the complement cascade
What are the common side effects of obinutuzumab?
Neutropenia, Hyperkalemia, Infusion related reactions, Hypocalcemia, Hyponatremia, Creatinine increased, AST/SGOT increased
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.